Cargando…

Effects Mediated by Dimethyl Fumarate on In Vitro Oligodendrocytes: Implications in Multiple Sclerosis

Background: Dimethyl fumarate (DMF) is a drug currently in use in oral therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS) due to its immunomodulatory and neuroprotective effects. The mechanisms by which DMF exerts its therapeutic effects in MS and in particular its influence...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guerriero, Claudia, Puliatti, Giulia, Di Marino, Tamara, Tata, Ada Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8998768/ https://www.ncbi.nlm.nih.gov/pubmed/35408975 http://dx.doi.org/10.3390/ijms23073615

Ejemplares similares

Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes
por: Huang, He, et al.
Publicado: (2015)

COVID-19 in multiple sclerosis patients treated with dimethyl fumarate
por: Capone, Fioravante, et al.
Publicado: (2021)

Effectiveness and safety of dimethyl fumarate in progressive multiple sclerosis
por: Moreira Ferreira, Vanessa F, et al.
Publicado: (2021)

No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis
por: Piervincenzi, Claudia, et al.
Publicado: (2022)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis
por: Mantero, Vittorio, et al.
Publicado: (2020)

Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis
por: Buckle, Guy, et al.
Publicado: (2020)

Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate
por: Baharnoori, Moogeh, et al.
Publicado: (2016)

The Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis
por: Dupuy, Sheena L., et al.
Publicado: (2016)

The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis
por: Wicks, Paul, et al.
Publicado: (2016)

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis
por: Mills, Elizabeth A., et al.
Publicado: (2018)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis
por: Norborg, Hilde, et al.
Publicado: (2021)

Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions
por: Zinger, Nicole, et al.
Publicado: (2022)

Dimethyl Fumarate Was Ineffective but Not Harmful for a Patient with Myelin Oligodendrocyte Glycoprotein Antibody Disease
por: Warabi, Yoko, et al.
Publicado: (2019)

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate
por: Spencer, Collin M., et al.
Publicado: (2015)

Disseminated zoster with paresis in a multiple sclerosis patient treated with dimethyl fumarate
por: Ma, Brandy B., et al.
Publicado: (2016)

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations
por: Prosperini, Luca, et al.
Publicado: (2016)

Dimethyl fumarate inhibits integrin α4 expression in multiple sclerosis models
por: Kihara, Yasuyuki, et al.
Publicado: (2015)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

The NRF2 pathway as potential biomarker for dimethyl fumarate treatment in multiple sclerosis
por: Hammer, Anna, et al.
Publicado: (2018)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Lymphocyte subtypes in relapsing–remitting multiple sclerosis patients treated with dimethyl fumarate
por: Chaves, C, et al.
Publicado: (2017)

HDL-cholesterol elevation associated with fingolimod and dimethyl fumarate therapies in multiple sclerosis
por: Blumenfeld Kan, S, et al.
Publicado: (2019)

Progressive multifocal leukoencephalopathy outcomes in patients with multiple sclerosis treated with dimethyl fumarate
por: Lyons, Jennifer, et al.
Publicado: (2022)

Gut Microbiota Changes during Dimethyl Fumarate Treatment in Patients with Multiple Sclerosis
por: Ferri, Caterina, et al.
Publicado: (2023)

The effects of dimethyl fumarate and fingolimod on T-cell lymphocyte proliferation in patients with multiple sclerosis
por: Reynolds, Audrey, et al.
Publicado: (2022)

Acute exacerbation of Hashimoto's thyroiditis in a patient treated with dimethyl fumarate for multiple sclerosis: A case report
por: Ciurleo, Rosella, et al.
Publicado: (2019)

Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
por: Nicholas, Jacqueline Ann, et al.
Publicado: (2014)

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
por: Kappos, L, et al.
Publicado: (2015)

Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets
por: Lundy, Steven K., et al.
Publicado: (2016)

Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis
por: Ciolac, Dumitru, et al.
Publicado: (2019)

Utilization of Dimethyl Fumarate and Related Molecules for Treatment of Multiple Sclerosis, Cancer, and Other Diseases
por: Al-Jaderi, Zaidoon, et al.
Publicado: (2016)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives
por: Ozel, Osman, et al.
Publicado: (2019)

The Age-Related Efficacy of Dimethyl Fumarate and Natalizumab in the Real-World Management of Multiple Sclerosis
por: De Masi, Roberto, et al.
Publicado: (2021)

Dimethyl Fumarate-Induced Takotsubo Cardiomyopathy in a Patient With Relapsing-Remitting Multiple Sclerosis
por: Srichawla, Bahadar S
Publicado: (2022)

Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis
por: Hou, Jue, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_elhp6k5o29qocmf0ddcfouvu6s